<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543725</url>
  </required_header>
  <id_info>
    <org_study_id>CR002704</org_study_id>
    <secondary_id>TMC278-TIDP6-C215</secondary_id>
    <nct_id>NCT00543725</nct_id>
    <nct_alias>NCT00614692</nct_alias>
  </id_info>
  <brief_title>TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors</brief_title>
  <official_title>A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec Pharmaceuticals, Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec Pharmaceuticals, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278
      given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily,
      when combined with a background regimen containing 2 nucleoside/nucleotide reverse
      transcriptase inhibitors ( investigator choice of ABC/3TC, TDF/FTC or AZT/3TC) in HIV-1
      infected patients who have not yet taken any anti-HIV drugs. The following evaluations will
      be done: antiviral activity, immunologic changes, and viral geno-/phenotype evolution,
      relationship of Pharmacokinetics (PK) and PK/Pharmacodynamics and Medical resource
      utilization and treatment adherence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past decade, anti-human immunodeficiency virus (HIV) drugs have been introduced
      sequentially for use in the clinic. Currently, patients are routinely being treated with 3 or
      4 drug combinations including nucleoside/tide analogue reverse transcriptase inhibitors
      (NRTIs/NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors
      (PIs), and/or fusion inhibitors. New potent antiretroviral (ARV) compounds that work in
      people whose HIV-1 virus is resistant to available drugs are urgently needed. This is a Phase
      III, randomized (study medication is assigned by chance), double-blind (neither the study
      physician nor the patient knows the name of the study assigned medication), double-dummy,
      active-controlled trial to compare the effectiveness, safety, and ability to tolerate TMC278
      versus efavirenz (EFV). The study will last for 104 weeks which includes a screening period
      of 4 weeks, a 96-week treatment period, followed by a 4 week follow-up period. Patients will
      be randomly assigned (like tossing a coin) to TMC278 or to efavirenz in combination with two
      other anti-HIV drugs of the class nucleoside/nucleotide reverse transcriptase inhibitors. The
      hypothesis to be provided in this study is that the investigational drug TMC278 will perform
      just like efavirenz (EFV) in terms of antiviral effectiveness (i.e., suppressing of the
      plasma viral load to a level &lt; 50 HIV-1 RNA (ribonucleic acid) copies/mL, in ARV-na√Øve
      HIV-infected patients. During the trial, patients' health will be monitored by physical
      examination, interview to assess health and well being, and laboratory testing on blood and
      urine samples. Experimental Group: One tablet of TMC278 25 mg daily; plus efavirenz (EFV)
      placebo; plus 2 nucleoside/nucleotide reverse transcriptase inhibitors; Control Group: One
      tablet of Placebo daily that looks just like TMC278 plus EFV 600 mg daily plus 2
      nucleoside/nucleotide reverse transcriptase inhibitors for 104 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Virological response is defined as confirmed plasma viral load less than (&lt;) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load &lt;50 copies/ml).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL&lt;50 copies/mL (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL&gt;=50 copies/mL in the Wk 48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL&gt;=50 copies/mL and subjects who had a switch in background regimen that was not permitted by the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Observed, &lt;50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).</measure>
    <time_frame>Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz</time_frame>
    <description>Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per mL at the last on-treatment post-Week 96 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 96. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)</measure>
    <time_frame>Baseline, Week 48, and Week 96</time_frame>
    <description>Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure</measure>
    <time_frame>Week 96</time_frame>
    <description>Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load &lt;50 copies/mL) and plasma viral load increase of &gt;=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">680</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>efavirenz 600 mg tablet once daily for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC278 25 mg tablet once daily for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC278</intervention_name>
    <description>25 mg tablet once daily for 96 weeks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>600 mg tablet once daily for 96 weeks</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with documented HIV-1 infection

          -  Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to
             screening

          -  Patient's HIV-1 plasma viral load at screening is &gt; 5,000 HIV-1 RNA copies/mL (assayed
             by RNA PCR standard specimen procedure)

          -  Patient's virus is sensitive to the 2 nucleoside/nucleotide reverse transcriptase
             inhibitors chosen for treatment

          -  Patient agrees not to start ART before the baseline visit

          -  Patient is HLA-B*5701 negative in case abacavir is included in the patient's treatment
             regimen.

        Exclusion Criteria:

          -  Previous use of ANY ARV drug for ANY length of time

          -  Any documented evidence of NNRTI resistance associated mutations in patient's HIV

          -  Category C AIDS defining illness, except, Stable Kaposi Sarcoma Wasting syndrome if
             not progressive

          -  Pneumocystis carinii pneumonia (PCP) that is considered not cured

          -  Active TB

          -  Allergy or hypersensitivity to study or background ARTs

          -  Specific grade 3 or 4 toxicity

          -  Kidney impairment: calculated creatinine clearance &lt;50 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec Pharmaceuticals, Ireland Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec Pharmaceuticals, Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surry Hills</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Distrito Barao Geraldo-Campina</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinheiros</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>K√∂ln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara N/A</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City N/A</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria N/A</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westdene Johannesburg Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Costa Rica</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <results_first_submitted>June 14, 2011</results_first_submitted>
  <results_first_submitted_qc>June 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2011</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiretroviral</keyword>
  <keyword>HIV-1</keyword>
  <keyword>AIDS</keyword>
  <keyword>TMC278-C215</keyword>
  <keyword>TMC278-TiDP6-C215</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-na√Øve HIV-1 infected subjects</recruitment_details>
      <pre_assignment_details>680 participants were randomized (340 in TMC 278 and 340 in efavirenz) but only 338 participants were treated with efavirenz (2 were randomized but not treated).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TMC278</title>
          <description>25 mg tablet once daily</description>
        </group>
        <group group_id="P2">
          <title>Efavirenz</title>
          <description>600 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliant</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Ineligible To Continue The Trial</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Reached A Virologic Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TMC278</title>
          <description>25 mg tablet once daily</description>
        </group>
        <group group_id="B2">
          <title>Efavirenz</title>
          <description>600 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="340"/>
            <count group_id="B2" value="338"/>
            <count group_id="B3" value="678"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="9.39"/>
                    <measurement group_id="B2" value="36.4" spread="8.92"/>
                    <measurement group_id="B3" value="36.5" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region Enroll</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>USA, Canada, Europe, Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 48</title>
        <description>Virological response is defined as confirmed plasma viral load less than (&lt;) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load &lt;50 copies/ml).</description>
        <time_frame>Week 48</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 48</title>
          <description>Virological response is defined as confirmed plasma viral load less than (&lt;) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load &lt;50 copies/ml).</description>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to other reason than AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a response rate of 75% at 48 weeks for both treatment groups, 340 subjects were needed per treatment (TMC278 or EFV) to establish non-inferiority of TMC278 versus EFV with a maximum allowable difference of 12% and a 1-sided significance level of 2.5%, to yield 95% power.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significance level was set at 2.5% (one-sided). No adjustment of p-value for multiple comparisons, since there was only single comparison for the primary endpoint.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm and background NRTI regimen as factors, and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
            <estimate_desc>Difference in proportion responders was estimated through the logistic regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 48</title>
        <description>The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL&lt;50 copies/mL (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL&gt;=50 copies/mL in the Wk 48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL&gt;=50 copies/mL and subjects who had a switch in background regimen that was not permitted by the protocol.</description>
        <time_frame>Week 48</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 48</title>
          <description>The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL&lt;50 copies/mL (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL&gt;=50 copies/mL in the Wk 48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL&gt;=50 copies/mL and subjects who had a switch in background regimen that was not permitted by the protocol.</description>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virologic Response (&lt;50 copies/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No plasma viral load data in 48-week window</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm and background NRTI regimen as factors, and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
            <estimate_desc>Difference in proportion responders was estimated through the logistic regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 96</title>
        <time_frame>Week 96</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 96</title>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to other reason than AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a response rate of 75% at 48 weeks for both treatment groups, 340 subjects were needed per treatment (TMC278 or EFV) to establish non-inferiority of TMC278 versus EFV with a maximum allowable difference of 12% and a 1-sided significance level of 2.5%, to yield 95% power.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significance level was set at 2.5% (one-sided). No adjustment of p-value for multiple comparisons, since there was only single comparison for the primary endpoint.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm and background NRTI regimen as factors, and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
            <estimate_desc>Difference in proportion responders was estimated through the logistic regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 96</title>
        <time_frame>Week 96</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 96</title>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virologic response (&lt;50 copies/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No plasma viral load data in 96-Week window</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm and background NRTI regimen as factors, and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
            <estimate_desc>Difference in proportion responders was estimated through the logistic regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Observed, &lt;50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).</title>
        <description>Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per mL at the last on-treatment post-Week 96 visit.</description>
        <time_frame>Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz</time_frame>
        <population>Participants with at least 1 Post-Week 96 visit were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Observed, &lt;50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).</title>
          <description>Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per mL at the last on-treatment post-Week 96 visit.</description>
          <population>Participants with at least 1 Post-Week 96 visit were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 48</title>
        <description>Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</description>
        <time_frame>Week 48</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 48</title>
          <description>Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</description>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 96</title>
        <description>Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 96. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</description>
        <time_frame>Week 96</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 96</title>
          <description>Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 96. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</description>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)</title>
        <description>Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.</description>
        <time_frame>Baseline, Week 48, and Week 96</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)</title>
          <description>Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.</description>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>cells per microliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absolute cell count, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.6" lower_limit="173.98" upper_limit="203.15"/>
                    <measurement group_id="O2" value="170.7" lower_limit="154.55" upper_limit="186.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute cell count, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.5" lower_limit="217.40" upper_limit="251.55"/>
                    <measurement group_id="O2" value="212.0" lower_limit="193.70" upper_limit="230.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative cell count, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="7.68" upper_limit="8.85"/>
                    <measurement group_id="O2" value="8.0" lower_limit="7.39" upper_limit="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative cell count, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="9.35" upper_limit="10.75"/>
                    <measurement group_id="O2" value="9.7" lower_limit="8.95" upper_limit="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure</title>
        <description>Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load &lt;50 copies/mL) and plasma viral load increase of &gt;=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).</description>
        <time_frame>Week 96</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable (had data) for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 mg tablet once daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure</title>
          <description>Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load &lt;50 copies/mL) and plasma viral load increase of &gt;=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).</description>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable (had data) for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-emergent NNRTI RAM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E138K</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H221Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K101E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K103N</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V90I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V106M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V189I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y188C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent N(t)RTI RAM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K65R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K219E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M184I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M184V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 164 weeks for participants in the TMC278 treatment group and up to 144 weeks for participants in the efavirenz treatment group.</time_frame>
      <desc>Only participants who had at least one of the treatment-emergent adverse events (TEAEs) listed in the Other (non Serious) adverse event (AE) table are included in the total number of participants with Non-Serious AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>TMC278</title>
          <description>25 mg tablet once daily</description>
        </group>
        <group group_id="E2">
          <title>Efavirenz</title>
          <description>600 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Jejunitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cyclosporidium infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Encephalitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arthritis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>External ear cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis b</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Brain scan abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="253" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Leader</name_or_title>
      <organization>Janssen Infectious Diseases BVBA</organization>
      <phone>32 14 641418</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

